HER2-Positive Breast Cancer

>

Latest News

Dato-Dxd Shows Survival Improvements in HR+/HER2- Breast Cancer
Dato-Dxd Shows Survival Improvements in HR+/HER2- Breast Cancer

September 22nd 2023

The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor-positive, HER2-negative breast cancer were treated with datopotamab deruxtecan.

Trastuzumab Deruxtecan Revolutionizes Treatment in HER2+ Breast Cancer
Trastuzumab Deruxtecan Revolutionizes Treatment in HER2+ Breast Cancer

September 19th 2023

Trial to Assess DB-1303 in HER2-Low Metastatic Breast Cancer
Trial to Assess DB-1303 in HER2-Low Metastatic Breast Cancer

September 7th 2023

Neratinib Combo Shows Substantial Benefit in HER2-Mutant mBC
Neratinib Combo Shows Substantial Benefit in HER2-Mutant mBC

August 24th 2023

Tucatinib Plus T-DM1 Lowers Risk of Progression or Death in HER2+ mBC
Tucatinib Plus T-DM1 Lowers Risk of Progression or Death in HER2+ mBC

August 17th 2023

Video Series
Video Interviews
Podcasts

More News